Breast Cancer

A potential correlation between processed food and breast cancer has been discovered.

According to the FDA, patients should be selected based on an FDA-approved companion diagnostic test.

One in 8 women will develop breast cancer within their lifetime, making it the most commonly diagnosed cancer among women.

Women diagnosed with breast cancer while breastfeeding may receive treatments that decrease milk production or are contraindicated.

Researchers found that replacing 30 minutes of inactivity with exercise significantly reduces the risk of cancer-related death.

The intent of the study was to bring awareness to the medical and nonmedical financial hardships of cancer and how they can impact the use of preventive services, since there is little research available to evaluate this topic, according to the study authors.

Facing MBC Together is intended to recognize the prevalence and impact of isolation on the lives of individuals with metastatic breast cancer.

The updated guidelines include increased recommended physical activity levels and a growing emphasis on holistic rather than nutrient-based dietary habits.

In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.

Why was a customer prescribed an allergy medication when she was expecting a pain pill?

According to study findings published in Cancer, mammography screenings reduce the rates of advanced and fatal cancers by more than 40%.

The anti-cancer medicine venetoclax may improve the current therapy for estrogen receptor-positive (ER+) breast cancer.

Although the average wholesale price of the agents is more than $13,000, the investigators found that 9% of patients had a 0% co-pay throughout the 6-month period.

A community pharmacy-based intervention program was utilized to enhance AET adherence.

Sacituzumab govitecan-hziy, approved by the FDA on April 22, 2020, is the first in its class to treat metastatic, triple-negative breast cancer in patients who have received at least 2 prior therapies for metastatic disease.

In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.

According to the investigators, the cells are called ductal macrophages and function by consuming dying milk-producing cells, which need to be cleared away after milk production stops.

In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).

Researchers have developed a new way to map the molecules on tumor cells that flag their presence to the immune system.

The findings are part of the I-SPY clinical trial and were presented at the American Association for Cancer Research virtual annual meeting.

The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.

There are few effective treatment options for patients with HER2-positive breast cancer who have received 2 or more previous therapies for advanced disease, according to the study authors.

According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.

Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.

In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.

Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.

There are a variety of interventions that can be used to improve survival after a patient reports cancer toxicity following treatment.

LGBTQ patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce care gaps.

An expert panel at the Community Oncology Conference 2020 discussed how COVID-19 is changing the future of community oncology.

New research has identified the binding site where drug compounds could activate a key braking mechanism against the runaway growth of many types of cancer.